Results 21 to 30 of about 337 (145)

A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system

Scientific Reports
Tenosynovial giant cell tumor (TGCT) is a rare neoplasm closely associated with dysregulation of the colony-stimulating factor 1(CSF1)/CSF1R signaling pathway, faces high recurrence rates despite surgical intervention, prompting exploration of CSF1R ...
Dan Chen, Xia-wen Yang, Jing Fu, Deng-zheng Zhang, Guo-Qing Chen, Wei Cai, Wen-long Xie   +6 more
doaj   +2 more sources

Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

, 2022
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in ...
Stephen Patrick Anthony (11959735), Fadi Braiteh (14998773), William D. Tap (15017801), Gregory M. Cote (15036672), Brian L. West (8863253), John H. Healey (15036663), Henry H. Hsu (11959749), Sandra Tong-Starksen (11959746), Paul Severson (6868589), Mike Sterba (11959744), Allen Lee Cohn (11959738), Igor Puzanov (5198039), Vicki L. Keedy (15036669), Bartosz Chmielowski (15036666), Heather L. Gelhorn (12523522), Arun S. Singh (15036660), Zev A. Wainberg (9552988), Eric Sherman (3913357), Paul S. Lin (15036675), Geoffrey I. Shapiro (14961801), Chao Zhang (51048), Charles Peterfy (674120), Xin Ye (208347), Andrew J. Wagner (15021018)   +23 more
core   +6 more sources

Pexidartinib [PDF]

, 2020
openaire   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Correction to: Pexidartinib: First Approval [PDF]

Drugs, 2020
The original article has been corrected.
openaire   +2 more sources

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality

Clinical Pharmacology in Drug Development, 2022
AbstractPexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy subjects to determine the absorption, distribution, metabolism, and excretion of pexidartinib using radiolabeled drug and to assess the dose proportionality of
Zahir, Hamim, Greenberg, Jonathan, Hsu, Ching, Watanabe, Kengo, Makino, Chie, He, Ling, LaCreta, Frank   +6 more
openaire   +2 more sources

Potential Stereoselective Binding of Trans-(±)-Kusunokinin and Cis-(±)-Kusunokinin Isomers to CSF1R

Molecules, 2022
Breast cancer cell proliferation and migration are inhibited by naturally extracted trans-(−)-kusunokinin. However, three additional enantiomers of kusunokinin have yet to be investigated: trans-(+)-kusunokinin, cis-(−)-isomer and cis-(+)-isomer ...
Chompunud Chompunud Na Ayudhya, Potchanapond Graidist, Varomyalin Tipmanee   +2 more
doaj   +1 more source

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)

, 2022
Background Anaplastic thyroid cancer (ATC) is the greatest lethal thyroid neoplasm with a low incidence and lacks an effective treatment strategy and standardized treatment protocol.
Jingtao Luo, Yun Wang, Lingkun Zhao, Ze Zhang, Chunli Wang   +4 more
core   +1 more source

Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor

The Oncologist, 2023
Abstract Background Pexidartinib (Turalio) is the only systemic therapy approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant-cell tumor (TGCT) associated with severe morbidity or functional limitations, and not amenable to improvement with surgery.
Feng Lin, Winghan Jacqueline Kwong, Irene Pan, Xin Ye, Dong Dai, William Tap   +5 more
openaire   +2 more sources

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT [PDF]

, 2021
PURPOSE: To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity ...
Healey, John H., Ye, Xin, Gelhorn, Heather L, Puzanov, Igor, Wainberg, Zev A, Hsu, Henry H, West, Brian L, Cote, Gregory M., Keedy, Vicki L., Shapiro, Geoffrey I, Braiteh, Fadi, Gelhorn, Heather L., Wagner, Andrew J., Singh, Arun S., Hsu, Henry H., Tong-Starksen, Sandra, Sherman, Eric, Peterfy, Charles, Keedy, Vicki L, Wagner, Andrew J, Tap, William D., West, Brian L., Cohn, Allen Lee, Severson, Paul, Sterba, Mike, Tap, William D, Shapiro, Geoffrey I., Cote, Gregory M, Lin, Paul S., Singh, Arun S, Zhang, Chao, Chmielowski, Bartosz, Anthony, Stephen Patrick, Lin, Paul S, Wainberg, Zev A., Healey, John H   +35 more
core   +1 more source